NS Pharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nspharma.com
NS-050/NCNP-03 in Boys With DMD (Meteor50)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06053814
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis With Polyangiitis
- Conditions
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Ns Pharma Inc.
- Target Recruit Count
- 20
- Registration Number
- 2023-504245-32-00
- Locations
- 🇪🇸
Hospital Universitario De Navarra, Pamplona, Spain
🇪🇸Complexo Hospitalario Universitario De Santiago, Santiago De Compostela, Spain
🇫🇷Centre Hospitalier Universitaire De Nice, Nice, France
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05996003
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Rare Disease Research, Atlanta, Georgia, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04956289
- Locations
- 🇺🇸
Children's Hospital of Richmond at VCU, Richmond, Virginia, United States
🇨🇳The Third Medical Center of PLA General Hospital, Beijing, China
🇨🇳Hunan Children's Hospital, Changsha, China
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
- Conditions
- Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
- Interventions
- Drug: Best Available Therapy
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04854096
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT04768062
- Locations
- 🇦🇺
Queensland Children's Hospital, Brisbane, Australia
🇦🇺The Childrens Hospital at Westmead, Westmead, Australia
🇨🇦CHU de Quebec Research Centre, Quebec City, Canada
Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04687020
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation
- Conditions
- Muscular Dystrophy, DuchenneDMD
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- NS Pharma, Inc.
- Registration Number
- NCT04337112
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT04060199
- Locations
- 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇦🇺Queensland Children's Hospital, Brisbane, Australia
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03167255
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸Washington University, Saint Louis, Missouri, United States